A Ten-year Follow-up of IFN-α Antiviral Therapy in 118 Patients with Chronic Hepatitis B
Objective To investigate the efficacy of IFN-alpha antiviral therapy in patients with chronic hepatitis B(CHB)so as to provide a reference for CHB antiviral therapy in clinical prac-tice.Methods 118 patients with CHB who were treated with regular IFN-α and had complete data were included in the study;the patients'hepatitis B penta-scores[hepatitis B surface antigen(HBsAg),hepatitis B surface antibody(HBsAb),hepatitis B e antigen(HBeAg),hepatitis B e antibody(HBeAb),hepatitis B core antibody(HBcAb)],quantitative hepatitis B DNA(HBV-DNA)and alanine transaminase(ALT)levels were collected through regular outpatient follow-ups and telephone follow-ups.HBV-DNA and HBsAg negative conversion rates,HBeAg/HBeAb seroconversion rates,and ALT reversion rates were compared before and after treatment,and at different time points during the follow-up period.Results The HBV-DNA-negative rate and the HBsAg-negative rate increased with the duration of treatment:HBV-DNA-negative rate was sig-nificantly higher at the 24th,36th,and 48th weeks after treatment than at the 12th week;HB-sAg-negative rate was significantly higher at the 48th week than at the 12th and 24th weeks;the differences were statistically significant(P＜0.05).A decreasing and then stabilizing tendency in the HBV-DNA-negative rate and the HBsAg-negative rate was observed at each follow-up node from week 24 to 432 after discontinuation.The HBeAg/HBeAb seroconversion rate increased with the duration of treatment and it was significantly higher at the 48th week than at the 12th week(P＜0.05).A decreasing and then stabilizing tendency in the HBeAg/HBeAb seroconversion rate and the rate of sustained virological response was observed with the prolongation of discontinua-tion of the drug.After discontinuation,the differences in the HBeAg/HBeAb seroconversion rates were not statistically significant at each follow-up node(P＞0.05).The virological relapse rate in-creased first after drug discontinuation and registered a stabilizing trend at the 144th week of drug discontinuation.The ALT relapse rate showed a stabilizing trend at the 144th week of drug dis-continuation,and the ALT relapse rate at the 144th week of drug discontinuation was significantly higher than that at the 12th week of drug discontinuation(P＜0.05).Conclusion IFN-α antiviral therapy for CHB can be of positive clinical efficacy,with relatively high response rates for HBV-DNA-negative rate,HBsAg-negative rate,ALT reversion rate,and HBeAg/HBeAb conversion rate at each follow-up node after treatment and discontinuation.
NETL
NSTL
万方数据
